26 September 2019
: Case report
Pyridostigmine Suicidal Attempt in a Myasthenia Gravis Patient
Challenging differential diagnosis, Management of emergency care, Patient complains / malpractice, Rare disease, Adverse events of drug therapy
Mohammed Aref T. Malabaey1ABEF*, Ahad A. Al-Saud1ABEF, Yasser A. Alaska1ABEF, Afnan Almas1ABCEF, Almas Malik1ABCEFDOI: 10.12659/AJCR.917308
Am J Case Rep 2019; 20:1418-1421
Abstract
BACKGROUND: Pyridostigmine is a quaternary amine parasympathomymetic which inhibits acetylcholinesterase for the treatment of various conditions such as myasthenia gravis. Previously, no cases of pyridostigmine toxicity in human beings have been reported except the cases reported among the troops of Persian Gulf War.
CASE REPORT: A 47-year-old female intentionally ingested a high dose of pyridostigmine (Mestinon) and developed its toxic symptoms within 1 hour of ingestion. She was treated with injections of atropine and pralidoxime. The patient made an excellent recovery and responded to the classical treatment using atropine and pralidoxime. She was discharged on the second day of admission.
CONCLUSIONS: The authors demonstrated that pyridostigmine poisoning is self-limiting and well tolerated by young adults; however, unwanted effects of pyridostigmine on the heart has still to be considered which may become profound to the point of generating heart failure, syncope, or stress particularly in elderly patients. As the literature on human toxicity with pyridostigmine is scarce, not much data is available on its toxicity. However, prompt and specific management of pyridostigmine toxicity promises safety.
Keywords: Drug Overdose, Myasthenia Gravis, Pyridostigmine Bromide, Suicide, Attempted, Atropine, Cholinesterase Inhibitors, Cholinesterase Reactivators, Middle Aged, Muscarinic Antagonists, Pralidoxime Compounds
SARS-CoV-2/COVID-19
04 July 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.934468
29 June 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936896
16 June 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936498
13 June 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936889
In Press
07 Jul 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.937305
06 Jul 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936313
05 Jul 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936585
05 Jul 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.935885
Most Viewed Current Articles
23 Feb 2022 : Case report
DOI :10.12659/AJCR.935250
Am J Case Rep 2022; 23:e935250
17 Feb 2022 : Case report
DOI :10.12659/AJCR.934399
Am J Case Rep 2022; 23:e934399
06 Dec 2021 : Case report
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
09 Feb 2022 : Case report
DOI :10.12659/AJCR.934744
Am J Case Rep 2022; 23:e934744